Non-Small Cell Lung Cancer Clinical Trial
Official title:
A Randomized, Double-Blind, Two-Way Crossover, Bioequivalence Study of SID530 and Taxotere® in Study Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Platinum Therapy Failure or Study Participants With Locally Advanced or Metastatic Breast Cancer Who Have Failed At Least One Prior Chemotherapeutic Regimen
Verified date | August 2010 |
Source | SK Chemicals Co.,Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This is a multi-center, randomized, blinded, two-period, two-sequence, crossover study, with
a minimum 3-week washout period between treatments.The study is designed to evaluate the
bioequivalence of SID530 to Taxotere.
It will be conducted in study participants with locally advanced or metastatic NSCLC who
have failed platinum therapy and also in participants with locally advanced or metastatic
breast cancer who have failed at least one line of chemotherapy.
Eligible study participants must be planning to have at least two consecutive 21-day cycles
with 75 mg/m2 docetaxel monotherapy.
The duration of study participation will be approximately 7 weeks. The study has three study
phases: Screening (<=1 week), Cycle 1 (21 days), and Cycle 2 (21 days).
Status | Completed |
Enrollment | 42 |
Est. completion date | January 2011 |
Est. primary completion date | January 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria:Study participants - Has provided written informed consent - Is at least 18 years of age - Has histologically or cytologically confirmed non-small cell lung (NSCLC) or breast cancer (BC) that is locally advanced or metastatic - Has at least two planned consecutive 21-day cycles with 75 mg/m2 docetaxel monotherapy - Has a life expectancy of at least 3 months - Has Eastern Cooperative Oncology Group Performance Scale (ECOG PS) is in the range of 0-2 at the time of randomization - Has the Proper laboratory values within 1 week prior to randomization - Has negative serum pregnancy test within 1 week before first study drug administration (for women of childbearing potential, only) - Is willing to practice medically accepted contraception (if the risk of conception exists) throughout the study period (from Screening until the Final Visit) Exclusion Criteria:Study participants - Has had any chemotherapy within 4 weeks before date of first study treatment - Has experienced severe side effects from (or severe hypersensitivity to) prior docetaxel treatment (or other drugs formulated with polysorbate 80, hydroxypropylbetadex, or povidone) such that discontinuation of the treatment was required - Has a history of hypersensitivity to dexamethasone - Is pregnant, lactating, or breastfeeding - Is taking one or more compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4 - Has had treatment in another clinical study within the past 30 days - Has medical or psychological conditions that would not permit the study participant to complete the study or sign informed consent - Is unlikely to comply with the protocol requirements, instructions and study-related restrictions - Has any other disease, dysfunction (including alcohol or drug abuse), physical examination or laboratory finding which, in the investigator's opinion, would exclude the participant from the study |
Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)
Country | Name | City | State |
---|---|---|---|
India | Kamakshi Memorial Hospital | No-1, Radial Road, Pallikarani | Chennai, Tamilnadu |
India | City Cancer Hospital | Vijayawada AndhraPradesh | Ch. venkatka Krishnayya |
United States | Gabrail Cancer Center | Canton | Ohio |
United States | Advanced Clinical Research Pharma | Miami | Florida |
Lead Sponsor | Collaborator |
---|---|
SK Chemicals Co.,Ltd. |
United States, India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | to test the bioequivalence of SID530 (test) to Taxotere | 7 weeks | Yes | |
Secondary | to evaluate the of safety and tolerability of SID530 as compared to the marketed Taxotere. | 7 weeks | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |